Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being the Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock, with the case pending in the U.S. District Court for the District of Minnesota [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Stock Performance and Issues - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in its 2025 earnings per share guidance by over 80% [7]. - The company cited undisclosed factors for the delays, including incomplete training at implanting centers and poor demand due to excess inventory of older devices [7][6]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota and claims that Inspire Medical and its executives concealed critical operational issues that hindered the successful launch of the Inspire V device [1][3]. - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are eligible to participate in the lawsuit [2]. Group 2: Allegations of Concealment - The lawsuit alleges that Inspire Medical misrepresented its "operational readiness" for the Inspire V launch, claiming it was prepared for a full commercial rollout, while in reality, significant operational failures existed [3][4]. - Key undisclosed operational issues include: - Medicare claims processing software updates were not effective until July 1, 2025, delaying the rollout and revenue generation [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V, leading to an 80% cut in 2025 EPS guidance [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 3: Investigation Focus - Hagens Berman's investigation emphasizes the concealment of the Medicare claims software failure and the inventory glut of the prior Inspire IV device as critical points leading to the stock collapse [5]. - The firm asserts that management prioritized a narrative of a seamless transition over the actual operational challenges faced [5].

On August 4, 2025, Inspire Medical Systems announced significant setbacks in the launch of its new Inspire V device. The company revealed that the rollout was taking much longer than expected because many treatment centers had not yet completed the required training, contracting, and onboarding needed to begin using the product. Inspire also disclosed billing and reimbursement challenges, explaining that although Medicare had approved a CPT code for Inspire V, the necessary software updates for claims proce ...

CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: In truth, the launch of the Company's new product, Inspire V, was a disaster because demand for Inspire V was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment. Moreover—and contrary to defendants' statements assuring investors that Inspire had taken all necessary steps to ensure a successful launch and, later, that the launch was in fact p ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock, with the case pending in the U.S. District Court for the District of Minnesota [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, but failed to prepare clinicians and payors, leading to significant delays and weak demand [5][6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand due to excess inventory of older devices [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary launch steps, leading to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top in securities class action settlements, recovering hundreds of millions for investors, including over $438 million in 2019 alone [4].

Inspire's Alleged Fraud NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G†) filed a class action in the U.S. District Court for the Southern District of New York alleging violations of the federal securities laws by Inspire Medical Systems, Inc. ("Inspire†or the "Company†) and certain of the Company's current senior executives (collectively, "Defendants†). The action is brought on behalf of all investors who purchased or otherwise ...

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Inspire securities between August 6, 2024 and August 4, 2025, b ...

Core Insights - Inspire Medical Systems (INSP) is positioned for growth due to a significant product transition, with management highlighting clinical momentum, improved reimbursement visibility, and disciplined cost control, despite facing near-term challenges related to inventory conversion and competition [2][12][14] Company Overview - Inspire Medical focuses on innovative, minimally-invasive solutions for obstructive sleep apnea, with a market capitalization of $2.81 billion. The company anticipates a 39.1% earnings decline for Q4 2025, but expects earnings growth to resume in 2026 [4] Financial Performance - INSP shares have decreased by 12.5% over the past six months, while the industry has declined by 16.3%, and the S&P 500 has increased by 16.3% during the same period [3] - The company has consistently surpassed earnings estimates in the last four quarters, achieving an average surprise of 164.19% [6] Positive Factors Driving Prospects - The launch of Inspire V is a key growth driver, with strong clinical data supporting its adoption, including reduced surgical times and high nightly usage. Adoption has accelerated, reaching over 75% of implanting centers [7] - Reimbursement trends are favorable, with an 11% increase in the physician fee schedule for CPT 64568 effective January 2026, enhancing the economic viability for hospitals [8][9] - The adoption of GLP-1 therapies is increasing patient flow into sleep clinics, which could lead to more referrals for Inspire Medical as noncompliance with CPAP emerges [10] Operational Discipline - The company has demonstrated operational discipline, achieving earnings upside through gross margin expansion and cost control, despite increased marketing expenses [11] Key Challenges - The transition from Inspire IV to Inspire V presents complexities, with some centers continuing to use Inspire IV for economic reasons, which complicates inventory forecasting [12] - Uncertainty exists around GLP-1 trialing, which may delay surgical interventions and impact short-term volume growth [13] - Elevated operating expenses and competition pose challenges to maintaining margin expansion, as operating expenses growth outpaces revenue growth [14] Estimate Trend - The Zacks Consensus Estimate for earnings in 2025 is $1.71 per share, with Q4 2025 revenue estimated at $262.9 million and a loss per share of 70 cents [15]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was expected to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to adequately prepare clinicians and payors for the rollout, leading to significant delays in adoption and weak demand due to existing inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].